Yoshimasa Sakamoto
Yoshimasa Sakamoto, Hyogo-Ken JP
Patent application number | Description | Published |
---|---|---|
20110008769 | DOPAMINERGIC NEURON PROGENITOR CELL MARKER 187A5 - An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein. | 01-13-2011 |
Yoshimasa Sakamoto, Kyoto JP
Patent application number | Description | Published |
---|---|---|
20080199437 | Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers - The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof. | 08-21-2008 |
20100216164 | MAMMALIAN PRICKLE GENE - The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia. | 08-26-2010 |
20100323366 | Methods of Selecting a Dopaminergic Neuron Proliferative Progenitor Cells Using LRP4/CORIN Markers - In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. | 12-23-2010 |
Yoshimasa Sakamoto, Kyoto-Fu JP
Patent application number | Description | Published |
---|---|---|
20100203505 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 08-12-2010 |
Yoshimasa Sakamoto, Kyoto-Shi JP
Patent application number | Description | Published |
---|---|---|
20080280301 | Lrp4/Corin DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKERS - In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. | 11-13-2008 |
20100028866 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Nato3 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 02-04-2010 |
20100203570 | GENE SPECIFICALLY EXPRESSED IN POSTMITOTIC DOPAMINERGIC NEURON PRECURSOR CELLS - A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease. | 08-12-2010 |
20110229889 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 09-22-2011 |
20120021417 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Nato3 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 01-26-2012 |
Yoshimasa Sakamoto, Nishinomiya JP
Patent application number | Description | Published |
---|---|---|
20120148592 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 06-14-2012 |
20140045215 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 02-13-2014 |
Yoshimasa Sakamoto, Chuo-Ku JP
Patent application number | Description | Published |
---|---|---|
20120213799 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine. | 08-23-2012 |
Yoshimasa Sakamoto, Kobe-Shi JP
Patent application number | Description | Published |
---|---|---|
20120252021 | DOPAMINERGIC NEURON PROGENITOR CELL MARKER 187A5 - An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein. | 10-04-2012 |
Yoshimasa Sakamoto, Kobe JP
Patent application number | Description | Published |
---|---|---|
20140193421 | Anti-Human XCR1 Antibodies - An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91. | 07-10-2014 |
20150299654 | Lrp4/CORIN DOPAMINE-PRODUCING NEURON PRECURSOR CELL MARKER - The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof. | 10-22-2015 |
Yoshimasa Sakamoto, Nishinomiya-Shi JP
Patent application number | Description | Published |
---|---|---|
20160046707 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 02-18-2016 |